Journal Article

DKFZ-2023-01305

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png A T-cell antigen atlas for meningioma: novel options for immunotherapy.

Medici, G. ; Freudenmann, L.DKFZ* ; Velz, J. ; Wang, S. S. ; Kapolou, K. ; Paramasivam, N.Extern* ; Mühlenbruch, L. ; Kowalewski, D. J.DKFZ* ; Vasella, F. ; Bilich, T.DKFZ* ; Frey, B. M. ; Dubbelaar, M. L. ; Patterson, A. B. ; Zeitlberger, A. M. ; Silginer, M. ; Roth, P. ; Weiss, T. ; Wirsching, H.-G. ; Krayenbühl, N. ; Bozinov, O. ; Regli, L. ; Rammensee, H.-G.DKFZ* ; Rushing, E. J. ; Sahm, F.DKFZ* ; Walz, J. S.DKFZ* ; Weller, M. ; Neidert, M. C.

2023
Springer Heidelberg

This record in other databases:  

Please use a persistent id in citations: doi:10.1007/s00401-023-02605-w

Abstract: Meningiomas are the most common primary intracranial tumors. Although most symptomatic cases can be managed by surgery and/or radiotherapy, a relevant number of patients experience an unfavorable clinical course and additional treatment options are needed. As meningiomas are often perfused by dural branches of the external carotid artery, which is located outside the blood-brain barrier, they might be an accessible target for immunotherapy. However, the landscape of naturally presented tumor antigens in meningioma is unknown. We here provide a T-cell antigen atlas for meningioma by in-depth profiling of the naturally presented immunopeptidome using LC-MS/MS. Candidate target antigens were selected based on a comparative approach using an extensive immunopeptidome data set of normal tissues. Meningioma-exclusive antigens for HLA class I and II are described here for the first time. Top-ranking targets were further functionally characterized by showing their immunogenicity through in vitro T-cell priming assays. Thus, we provide an atlas of meningioma T-cell antigens which will be publicly available for further research. In addition, we have identified novel actionable targets that warrant further investigation as an immunotherapy option for meningioma.

Keyword(s): HLA ligand ; Immunotherapy ; Meningioma ; T-cell immunotherapy ; Tumor-associated antigen

Note: 2023 Aug;146(2):173-190

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Tübingen (TU01)
2. KKE Neuropathologie (B300)
3. DKTK HD zentral (HD01)

Research Program(s):

1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2023

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DEAL Springer ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---